{"id":2775,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1980-03-17","marketCap":199.22817993164062,"name":"Vaxart Inc","phone":"16505503500","outstanding":152.0399932861328,"symbol":"VXRT","website":"https://vaxart.com/","industry":"Biotechnology"},"price":1.13,"year":2024,"month":2,"day":1,"weekday":"Thursday","title":"Historical Volatility of Vaxart Inc Stock and its Impact on Investor Behavior","date":"2024-02-01","url":"/posts/2024/02/01/VXRT","content":[{"section":"Understanding Historical Volatility","text":"Historical volatility refers to the measure of how much the price of a stock has fluctuated over a given time period. It is calculated using historical price data and is expressed as a percentage. A higher historical volatility suggests that the stock's price has experienced larger price swings, indicating higher risk."},{"section":"Impact on Investor Behavior","text":"The historical volatility of Vaxart Inc stock has influenced investor behavior in multiple ways. Firstly, it has affected the decision-making process of investors, especially those looking for short-term gains. Higher volatility may attract traders looking to capitalize on short-term price movements, leading to increased trading activity."},{"section":"Behavioral Biases","text":"Another impact of historical volatility on investor behavior is related to behavioral biases. High volatility can trigger emotional responses and irrational decision-making, such as panic selling during market downturns or irrational exuberance during bull markets. Investors may also exhibit a preference for less volatile stocks due to aversion to risk."},{"section":"Risk Management","text":"Historical volatility plays a crucial role in risk management strategies. Investors use historical volatility to assess the risk-reward tradeoff of investing in a particular stock. It helps determine the appropriate position sizing, and investors may adjust their portfolios based on their risk tolerance and the historical volatility of Vaxart Inc stock."},{"section":"Options Trading and Volatility","text":"Historical volatility is particularly relevant in options trading, where option prices are influenced by the perceived volatility of the underlying stock. Higher historical volatility tends to increase option prices, indicating an elevated level of risk. Options traders may employ strategies like straddles or strangles to capitalize on anticipated volatility."},{"section":"Strategies for Dealing with Volatility","text":"Investors can adopt various strategies to manage the impact of historical volatility. Diversification, spreading investments across different asset classes or sectors, can help reduce the overall portfolio risk. Utilizing stop-loss orders or trailing stops can provide downside protection and limit potential losses. Additionally, long-term investors may choose to ignore short-term volatility and focus on the fundamental strength of the company."},{"section":"Conclusion","text":"The historical volatility of Vaxart Inc stock has influenced investor behavior, leading to increased trading activity and potentially triggering behavioral biases. Risk management strategies, such as diversification and the use of stop-loss orders, are employed to manage the impact of volatility. It is important for investors to assess historical volatility accurately and understand its implications when making investment decisions."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1705671000,"headline":"Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate","id":125190603,"image":"https://media.zenfs.com/en/globenewswire.com/1ebc0e3426d7a318cee9cb215c0e1e4a","symbol":"VXRT","publisher":"Yahoo","summary":"- 10,000-subject Phase 2b study would evaluate Vaxartâ€™s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 - SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that the United States Biomedical Adva","url":"https://finance.yahoo.com/news/vaxart-receives-9-27-million-133000678.html"},{"category":"company","date":1705659900,"headline":"Biotech Alert: Searches spiking for these stocks today","id":125175462,"image":"","symbol":"VXRT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3307812041"},{"category":"company","date":1705659480,"headline":"Vaxart gets BARDA funding for Phase 2 study of COVID-19 pill vaccine","id":125188448,"image":"","symbol":"VXRT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3307804061"},{"category":"company","date":1705649520,"headline":"Vaxart receives $9.27M BARDA project award for Phase 2B trial on oral pill","id":125188450,"image":"","symbol":"VXRT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3307614165"}]}